Clinical Trials Browser

Adenocarcinoma × Trastuzumab × 30 days × Clear all

NCT04309578 2026-04-03

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Phase 2 Completed

Adenocarcinoma